{"id":"intranasal-mupirocin-and-topical-chlorhexidine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasal irritation or discomfort"},{"rate":null,"effect":"Local allergic reaction"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mupirocin is a topical antibiotic that inhibits bacterial protein synthesis by binding to isoleucyl-tRNA synthetase, effectively killing susceptible bacteria in the nasal cavity. Chlorhexidine is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins. Together, this combination targets and eradicates nasal carriage of antibiotic-resistant pathogens, reducing the risk of subsequent infection.","oneSentence":"Intranasal mupirocin and topical chlorhexidine work together to eliminate and prevent nasal colonization of pathogenic bacteria, particularly Staphylococcus aureus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:47.364Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of surgical site infections by reducing nasal Staphylococcus aureus colonization"},{"name":"Decolonization of methicillin-resistant Staphylococcus aureus (MRSA) nasal carriage"}]},"trialDetails":[{"nctId":"NCT06712433","phase":"PHASE2","title":"Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)","status":"NOT_YET_RECRUITING","sponsor":"Adam Olson","startDate":"2026-09-30","conditions":"Sarcoma,Soft Tissue","enrollment":31},{"nctId":"NCT03140423","phase":"PHASE4","title":"Mupirocin-Iodophor ICU Decolonization Swap Out Trial","status":"COMPLETED","sponsor":"Harvard Pilgrim Health Care","startDate":"2017-05-01","conditions":"Staphylococcus Aureus","enrollment":353323},{"nctId":"NCT05505214","phase":"PHASE2","title":"Topical Steroids & Bacterial Decolonization for Radiation Dermatitis","status":"WITHDRAWN","sponsor":"Montefiore Medical Center","startDate":"2023-09-01","conditions":"Radiation Dermatitis","enrollment":""},{"nctId":"NCT04218799","phase":"PHASE4","title":"Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2014-08-12","conditions":"Human Microbiome","enrollment":19},{"nctId":"NCT04222699","phase":"PHASE4","title":"Cultures Before and After Decolonization in Community Dwelling Adults With Current S. Aureus Colonization","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2012-09-18","conditions":"Human Microbiome","enrollment":58},{"nctId":"NCT02063867","phase":"NA","title":"Active Bathing to Eliminate Infection (ABATE Infection) Trial","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2014-04","conditions":"Healthcare Associated Infections, Methicillin Resistant Staphylococcus Aureus, Multi Drug Resistant Organisms","enrollment":53},{"nctId":"NCT00980980","phase":"NA","title":"Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)","status":"COMPLETED","sponsor":"Harvard Pilgrim Health Care","startDate":"2009-09","conditions":"Methicillin-resistant Staphylococcus Aureus","enrollment":74256},{"nctId":"NCT01232231","phase":"NA","title":"Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus (MRSA) in the Outpatient Setting","status":"COMPLETED","sponsor":"Joseph Kim","startDate":"2010-07","conditions":"Methicillin-resistant Staphylococcus Aureus","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Intranasal Mupirocin and Topical Chlorhexidine","genericName":"Intranasal Mupirocin and Topical Chlorhexidine","companyName":"University of Maryland, Baltimore","companyId":"university-of-maryland-baltimore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intranasal mupirocin and topical chlorhexidine work together to eliminate and prevent nasal colonization of pathogenic bacteria, particularly Staphylococcus aureus. Used for Prevention of surgical site infections by reducing nasal Staphylococcus aureus colonization, Decolonization of methicillin-resistant Staphylococcus aureus (MRSA) nasal carriage.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}